Richard A Feelders Selected Research

Vipoma (WDHA)

1/2019	Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors.
4/2008	Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Richard A Feelders Research Topics

Disease

43	Neoplasms (Cancer) 06/2022 - 04/2005
25	Cushing Syndrome 03/2022 - 01/2003
21	Neuroendocrine Tumors (Neuroendocrine Tumor) 07/2022 - 01/2006
13	Adrenocortical Carcinoma 01/2021 - 11/2006
10	Neoplasm Metastasis (Metastasis) 07/2022 - 01/2005
10	Adenoma (Adenomas) 01/2017 - 01/2003
9	Pituitary Neoplasms (Pituitary Adenoma) 01/2021 - 11/2006
7	ACTH-Secreting Pituitary Adenoma 01/2021 - 08/2005
7	Acromegaly 01/2017 - 07/2005
6	Pituitary ACTH Hypersecretion 01/2022 - 01/2010
6	Carcinoid Tumor (Carcinoid) 01/2021 - 01/2005
6	Hyperplasia 05/2017 - 01/2003
5	Fibrosis (Cirrhosis) 04/2022 - 01/2017
5	Pheochromocytoma 04/2022 - 04/2008
4	Paraganglioma (Paragangliomas) 04/2022 - 10/2006
4	Rheumatoid Arthritis 10/2013 - 01/2010
3	Thrombocytopenia (Thrombopenia) 07/2022 - 03/2010
3	Prolactinoma (Prolactinomas) 09/2021 - 09/2008
3	Diarrhea 01/2021 - 01/2017
3	Adrenal Insufficiency (Adrenal Gland Hypofunction) 11/2019 - 01/2007
3	Heart Failure 07/2019 - 05/2010
3	Primitive Neuroectodermal Tumors (PNET) 01/2019 - 08/2017
3	Insulinoma 01/2019 - 09/2011
2	Nausea 01/2022 - 01/2021
2	Flushing 01/2021 - 01/2017
2	Hyperglycemia 01/2021 - 12/2013
2	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2019 - 10/2006
2	Polycythemia (Erythrocytosis) 01/2019 - 01/2017
2	Vipoma (WDHA) 01/2019 - 04/2008
2	Adrenal Cortex Neoplasms (Adrenocortical Cancer) 01/2019 - 01/2014
2	Gastrinoma 01/2019 - 01/2017
2	Hypertension (High Blood Pressure) 01/2018 - 11/2011
2	Adrenocortical Adenoma (Disease, Conn's) 08/2014 - 02/2012
1	Hypernatremia 06/2022
1	Hyponatremia 06/2022

Drug/Important Bio-Agent (IBA)

24	Hydrocortisone (Cortisol)FDA LinkGeneric 03/2022 - 01/2003
23	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 01/2021 - 04/2005
17	Somatostatin Receptors (Somatostatin Receptor)IBA 11/2020 - 04/2005
15	Adrenocorticotropic Hormone (ACTH)FDA Link 01/2021 - 01/2003
10	Messenger RNA (mRNA)IBA 01/2022 - 01/2003
7	Proteins (Proteins, Gene)FDA Link 04/2022 - 01/2013
7	GlucocorticoidsIBA 01/2020 - 01/2010
6	Radioisotopes (Radionuclides)IBA 01/2022 - 04/2008
6	Peptide Receptors (Peptide Receptor)IBA 01/2022 - 01/2016
6	Hormones (Hormone)IBA 03/2019 - 01/2003
6	Cabergoline FDA LinkGeneric 01/2019 - 06/2008
6	Octreotide (Sandostatin)FDA LinkGeneric 01/2019 - 01/2005
5	lutetium Lu 177 dotatateIBA 07/2022 - 01/2019
5	Mitotane (Lysodren)FDA Link 03/2022 - 06/2013
5	Glucocorticoid Receptors (Glucocorticoid Receptor)IBA 01/2022 - 08/2004
5	Dopamine Agonists (Dopamine Agonist)IBA 09/2021 - 09/2008
5	Ketoconazole (Nizoral)FDA LinkGeneric 01/2021 - 05/2010
4	AlbuminsIBA 07/2022 - 11/2011
4	Serotonin (5 Hydroxytryptamine)IBA 04/2022 - 01/2017
4	SteroidsIBA 01/2022 - 05/2010
4	Pharmaceutical PreparationsIBA 01/2021 - 01/2019
4	pasireotideIBA 01/2019 - 11/2009
4	Dopamine (Intropin)FDA LinkGeneric 01/2019 - 06/2008
4	Biomarkers (Surrogate Marker)IBA 01/2019 - 02/2012
4	Growth Hormone (Somatotropin)IBA 01/2017 - 11/2009
3	CatecholaminesIBA 04/2022 - 09/2013
3	AcidsIBA 01/2021 - 01/2017
3	Insulin-Like PeptidesIBA 09/2019 - 09/2011
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 09/2019 - 01/2018
3	177Lu-octreotateIBA 01/2016 - 04/2005
3	EnzymesIBA 09/2013 - 12/2007
3	Dopamine Receptors (Dopamine Receptor)IBA 02/2013 - 04/2007
2	Alkaline PhosphataseIBA 07/2022 - 06/2022
2	SodiumIBA 06/2022 - 01/2018
2	Adrenergic Receptors (Adrenergic Receptor)IBA 04/2022 - 01/2020
2	relacorilantIBA 01/2022 - 01/2021
2	OsilodrostatIBA 01/2022 - 01/2019
2	LutetiumIBA 01/2021 - 01/2019
2	ArrestinsIBA 01/2020 - 05/2016
2	ArrestinIBA 01/2020 - 05/2016
2	Peptides (Polypeptides)IBA 01/2019 - 01/2018
2	MTOR InhibitorsIBA 01/2019 - 06/2012
2	Circulating Tumor DNAIBA 01/2019 - 10/2017
2	RNA (Ribonucleic Acid)IBA 01/2019 - 01/2003
2	Metyrapone FDA Link 01/2019 - 11/2005
2	ErbB Receptors (EGF Receptor)IBA 01/2019 - 07/2013
2	Phosphopyruvate Hydratase (Enolase)IBA 07/2016 - 01/2016
2	Chromogranin AIBA 07/2016 - 01/2016
2	Sirolimus (Rapamycin)FDA Link 06/2016 - 08/2014
2	Everolimus FDA Link 12/2013 - 09/2011
2	Inhibins (Inhibin)IBA 09/2013 - 02/2012
2	InterferonsIBA 06/2013 - 11/2006
2	AldosteroneIBA 11/2011 - 05/2010
2	Insulin-Like Growth Factor I (IGF-1)IBA 09/2011 - 07/2005
2	pegvisomant FDA LinkGeneric 09/2011 - 12/2007
2	Dopamine D2 Receptors (Dopamine D2 Receptor)IBA 04/2007 - 11/2006
1	Hemoglobins (Hemoglobin)IBA 07/2022
1	ElectrolytesIBA 06/2022
1	Monoamine Oxidase (MAO)IBA 04/2022
1	ProteomeIBA 04/2022
1	Tryptophan (L-Tryptophan)FDA Link 04/2022

Therapy/Procedure

28	Therapeutics 01/2022 - 01/2005
4	Drug Therapy (Chemotherapy) 01/2021 - 06/2013
3	Adrenalectomy 12/2021 - 04/2012
3	Radiotherapy 01/2016 - 01/2006